Cathie Wood's ARK Invest Buys Over 1.5 Million Shares of Allogene

Investing

Published: December 15, 2021 7:40 am

One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 1.5 million shares of Allogene Therapeutics Inc. (NASDAQ: ALLO) on Tuesday. The price of this ETF was down more than 1% in Tuesday’s session, and it is down a fair amount in the past year.
[in-text-ad]
It was the ARK Genomic Revolution ETF (NYSEARCA: ARKG) that added 1,581,099 shares of Allogene. At Tuesday’s closing price, this would have valued this purchase at roughly $22.6 million. This is only a small fraction of the total holdings. The ETF is down roughly 37% in the past year.

Check out all of ARK Invest’s buys for Tuesday:

Fund	Ticker	Name	Shares
ARKF	AMZN	AMAZON.COM	71
ARKF	PINS	PINTEREST	50
ARKF	PAGS	PAGSEGURO DIGITAL	15,747
ARKF	FB	FACEBOOK	624
ARKG	PFE	PFIZER	80,672
ARKG	ALLO	ALLOGENE THERAPEUTICS	1,581,099
ARKG	REGN	REGENERON PHARMACEUTICALS	4,092
ARKK	IOVA	IOVANCE BIOTHERAPEUTICS	167,635
ARKK	EDIT	EDITAS MEDICINE	220,037
ARKK	PRLB	PROTO LABS	196
ARKQ	JD	JD.COM	56,925
ARKW	Z	ZILLOW	1,304
ARKW	SHOP	SHOPIFY	1,914
ARKW	LPSN	LIVEPERSON	203,247
ARKW	FTCH	FARFETCH	1,582
ARKW	FB	FACEBOOK	1,973
ARKX	BA	BOEING	141
ARKX	HOFP	THALES	46,027

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.

24/7 Wall St.
Why This Wall Street Firm Is Still Very Bullish on Semiconductors for 2022

ALERT: Take This Retirement Quiz Now (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.